Dr. Christine S. Sam, MD

Dr. Sam practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Sam's NPI, 1740543362, was assigned on June 19, 2012. Dr. Sam graduated from College of Human Medicine - Grand Rapids in 2012. Dr. Sam holds Florida license 123115.

Dr. Sam's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612. Dr. Sam also practices at H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., 10920 McKinley Dr, Tampa, FL 33612.

Dr. Sam's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Sam to 1 more breast imaging center, 1 group practice or clinic, 1 home health agency and 1 hospital outpatient department, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sam practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Sam's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Sam is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Sam's licenses on file in 3 states: Florida, North Carolina and Michigan.

Dmand AI lists chronic kidney disease and tobacco use among the conditions Dr. Sam treats.

CMS data shows 728 Medicare services from Dr. Sam across 5 procedure codes in 2024, all of them office visits, for 331 Medicare patients. Medicare paid $74,034 for them.

CMS counts 331 Medicare patients who saw Dr. Sam in 2024. The largest group is 75 to 84, with 185 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 2.29, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sam's median patient age at 78, with 72% women.

In 2024, Dr. Sam wrote 1,061 Medicare Part D claims for 319 patients. 84% of them were for generic drugs. CMS names the drug for 892 of them, across 23 drugs with 11 or more claims each, at $1,507,314 in total drug cost. In 2023, CMS named 808 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Sam for performance year 2024, reported as part of a group. Dr. Sam accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sam as offering telehealth.

Dmand AI links 9 papers to Dr. Sam, published from 2017 to 2025. 2022 was the busiest year, with 2. The most frequent topics are Breast Neoplasms, Immune Checkpoint Inhibitors and Neoadjuvant Therapy. Dr. Sam's most frequent co-authors are Mohammed Ameir Abdul Karim Al-Jumayli, MD, Martine Extermann, MD and Christine Laronga, MD.

CMS Open Payments shows 9 general payments to Dr. Sam from 8 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 90% of the total. Eli Lilly and Company paid the most, $158.

Dr. Sam graduated from College of Human Medicine - Grand Rapids in 2012.

Dr. Sam is in network with 10 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. HMO plans come from the most carriers, 8. Check the plan with the practice before a visit.